Literature DB >> 10416822

In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.

A Fredriksson1, P Johnström, J O Thorell, G von Heijne, M Hassan, S Eksborg, P Kogner, P Borgström, M Ingvar, S Stone-Elander.   

Abstract

The biodistribution of 11C-labeled 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, an inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase, has been evaluated in vivo in rats using positron emission tomography (PET). Time-activity data obtained after i.v. administration in one rat revealed that the radiotracer rapidly cleared from plasma with subsequent uptake in major organs of the body (brain, heart, liver, gastrointestinal tract and bladder). Uptake in proliferating tissue in rats with human neuroblastoma xenografts indicate that [O-11C-methyl]PD153035 shows promise as a new agent for in vivo imaging of tumors with PET.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416822     DOI: 10.1016/s0024-3205(99)00233-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

Authors:  Maria A Pantaleo; Eyal Mishani; Cristina Nanni; Lorena Landuzzi; Stefano Boschi; Giordano Nicoletti; Samar Dissoki; Paola Paterini; Pier Poalo Piccaluga; Filippo Lodi; Pier-Luigi Lollini; Stefano Fanti; Guido Biasco
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

Review 2.  The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.

Authors:  Antonia Högnäsbacka; Alex J Poot; Danielle J Vugts; Guus A M S van Dongen; Albert D Windhorst
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-05

Review 3.  Multimodality imaging of the HER-kinase axis in cancer.

Authors:  Weibo Cai; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

4.  Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Authors:  A Pal; A Glekas; M Doubrovin; J Balatoni; Mohammed Namavari; T Beresten; D Maxwell; S Soghomonyan; A Shavrin; L Ageyeva; R Finn; S M Larson; W Bornmann; J G Gelovani
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.484

5.  Stroma targeting nuclear imaging and radiopharmaceuticals.

Authors:  Dinesh Shetty; Jae-Min Jeong; Hyunsuk Shim
Journal:  Int J Mol Imaging       Date:  2012-05-21

6.  Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA.

Authors:  Skye Hsin-Hsien Yeh; Chien-Feng Lin; Fan-Lin Kong; Hsin-Ell Wang; Ya-Ju Hsieh; Juri G Gelovani; Ren-Shyan Liu
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

Review 7.  PET probes beyond (18)F-FDG.

Authors:  Lei Jiang; Yingfeng Tu; Hongcheng Shi; Zhen Cheng
Journal:  J Biomed Res       Date:  2014-04-15

Review 8.  [Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].

Authors:  Dong Dai; Wengui Xu; Qi Wang; Xiaofeng Li; Yanjia Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20

Review 9.  Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.

Authors:  Justin W Hicks; Henry F VanBrocklin; Alan A Wilson; Sylvain Houle; Neil Vasdev
Journal:  Molecules       Date:  2010-11-15       Impact factor: 4.411

Review 10.  Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Authors:  Eyal Mishani; Galith Abourbeh; Martin Eiblmaier; Carolyn J Anderson
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.